Board-certified internist says DVMs need to shape AI tools before consumer tech companies doBrakke Consulting framed fuel costs as a pass-through in its October newsletterAVMA greenlights Maryland Eastern Shore vet school, first public HBCU programAntech Accuplex showed higher Ehrlichia sensitivity than IDEXX SNAP 4Dx Plus in a JAVMA studyPractices underuse credentialed veterinary technicians while posting open positionsVetsource data shows practices unlikely to see pandemic puppy boom in senior yearsBoehringer Ingelheim launches quarterable Previcox tablets after FDA approvalHT VET scanner now identifies mast cell tumors and lipomas without biopsy in 1,010-dog studyBoard-certified internist says DVMs need to shape AI tools before consumer tech companies doBrakke Consulting framed fuel costs as a pass-through in its October newsletterAVMA greenlights Maryland Eastern Shore vet school, first public HBCU programAntech Accuplex showed higher Ehrlichia sensitivity than IDEXX SNAP 4Dx Plus in a JAVMA studyPractices underuse credentialed veterinary technicians while posting open positionsVetsource data shows practices unlikely to see pandemic puppy boom in senior yearsBoehringer Ingelheim launches quarterable Previcox tablets after FDA approvalHT VET scanner now identifies mast cell tumors and lipomas without biopsy in 1,010-dog study
Practice MoneyBy The VeterinaryPracticeNow Desk2 min readAugust 13, 2026
Which topical glaucoma drug actually works in sick eyes, and why we still don't know
A WSU student is comparing latanoprost, dorzolamide, and dorzolamide-timolol in dogs with naturally occurring disease.
Do latanoprost, dorzolamide, and dorzolamide-timolol actually preserve vision in dogs with naturally occurring primary glaucoma?
The plain answer
We don't know yet, because according to the Washington State University announcement, "much of the existing research has been conducted in healthy eyes or small, breed-specific populations," not in the clinical cases you see. A Washington State University Class of 2028 student, Lorelei Derenne, is running a two-phase study to answer exactly that: "a meta-analysis of existing literature and a retrospective review of clinical cases from a regional specialty eye clinic," the announcement says. The project, supervised by Dr. Travis Brown and Dr. Kevin Kaiser, will look at how the three most commonly prescribed topical glaucoma medications perform in dogs with disease that occurred naturally.
The caveat that makes it hard
The study design and methodology aren't detailed in the source, so we don't know what limitations the project will face or what the sample size will be. What we do know is that it's a student research fellowship project, which means the scope and timeline are constrained by the academic calendar and available resources. The findings will add to the evidence base, but how much they change practice will depend on the study's design and execution, details we'll see when the work is published.
What the three drugs do, and why the question matters
The source says these three treatments lower intraocular pressure through different mechanisms, and they're widely prescribed in practice. Derenne's project is designed to address a gap: the announcement says her work aims "to identify which treatments are most effective at preserving vision and slowing disease progression" by "comparing how these medications perform in dogs with naturally occurring glaucoma." That's the question the existing literature hasn't fully answered.
Watch for the published findings when they come out. Until then, the clinical decision stays the same: prescribe based on the evidence you have now, and be clear with owners about what we know and what we're still learning. The value of this project is that it's asking the right question, which of these drugs works best in real-world cases, and that question matters whether or not this particular study answers it definitively.
The research itself
Derenne is a Vancouver, Washington native with an undergraduate degree in Animal Sciences from WSU. Her stated interest is small animal medicine, ophthalmology, and pathology. The study has two phases: a meta-analysis of existing literature on the three medications, and a retrospective review of clinical cases from a regional specialty eye clinic. The goal, according to the announcement, is "to identify which treatments are most effective at preserving vision and slowing disease progression" in dogs with naturally occurring primary glaucoma. Derenne said "the project reflects both her academic interests" and her career goals: "This disease has a negative impact on the quality of life of many animals. I want to expand our knowledge of treating this disease and make a difference in the field of veterinary ophthalmology."
Get the next issue in your inbox. Free, weekly, no fluff.
